Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.
Jaime Grajales Benjumea—Getty Images
#MerckAstraZeneca #breast #cancer #drug #Lynparza #improves #longterm #survival #clinical #trial #shows